gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rizatriptan Benzoate

            Therapeutic Area: Neurology Product Name: Rizaport

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Exeltis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 27, 2020

            Details:

            Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine,Tetracaine

            Therapeutic Area: Neurology Product Name: Pliaglis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries Ltd.

            Deal Size: Undisclosed Upfront Cash: $3.9 million

            Deal Type: Licensing Agreement July 28, 2020

            Details:

            The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rizatriptan Benzoate

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 06, 2020

            Details:

            IntelGenx recently received from the U.S. FDA Complete Response Letter regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm®.